Neurocrine Biosciences Inc. (NBIX)
NASDAQ: NBIX · Biological Products, (No Diagnostic Substances) · San Diego, CA
Our rating: Positive
Positive reaffirmed at $164.85, moderate conviction, November 3, 2026.
Breaks if: The Positive view breaks if revenue growth in either of the next two reported periods comes in below 12% — a sharp enough deceleration to signal the core franchise is losing commercial altitude rather than maturing gracefully — or if trailing twelve-month free cash flow falls below $550M, indicating that cash conversion quality has deteriorated rather than held its current level. Either condition observed within the next twelve months would move the view to Neutral. On the upside, a second product reaching $300M or more in reported annual revenues with an independent patent runway would be the clearest evidence to revisit the case for Conviction.
Key figures
| Market value | $15.2B |
|---|---|
| Revenue, last 12 months | $3.7B |
| Net income, last 12 months | $703M |
| Free cash flow, last 12 months | $1.0B |
| Price to earnings | 21.7× |
| Free cash flow yield | 6.8% |
| Dividend yield | 0.0% |
| Operating margin | 24.0% |
| Return on equity | 20.4% |
| Beta to the S&P 500 | 0.77 |
| Volatility, annualized | 36.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.1B | 41.2% | $1.96 | $384M |
| June 30, 2026 | $959M | 39.5% | $1.39 | $129M |
| March 31, 2026 | $815M | 42.2% | $1.91 | $137M |
| December 31, 2025 | $806M | 28.3% | $1.48 | $391M |
| September 30, 2025 | $795M | 27.8% | $2.04 | $214M |
| June 30, 2025 | $688M | 16.5% | $1.06 | $90M |
| March 31, 2025 | $573M | 11.1% | $0.08 | $54M |
| December 31, 2024 | $628M | 21.8% | $1.00 | $235M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.11B: Claude 82%, Gemini 90%, Mistral 94%
- Diluted earnings per share are at least $1.48: Claude 58%, Gemini 80%, Mistral 78%
- Free cash flow for the quarter is at least $0.39B: Claude 62%, Gemini 65%, Mistral 62%
16 ledger entries and 29 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.